Calendrier des promotions PolyPid Ltd.
Calendrier avancé
Graphique simple
À propos de l'entreprise
PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| IPO date |
2020-06-26 |
| ISIN |
IL0011326795 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.polypid.com
|
| Цена ао |
4.84 |
| Changement de prix par jour: |
+1.4% (2.85) |
| Changement de prix par semaine: |
-10.25% (3.22) |
| Changement de prix par mois: |
-16.35% (3.455) |
| Changement de prix sur 3 mois: |
-20.17% (3.62) |
| Changement de prix sur six mois: |
-27.75% (4) |
| Changement de prix par an: |
-23.95% (3.8) |
| Evolution du prix sur 3 ans: |
-49.48% (5.72) |
| Evolution du prix sur 5 ans: |
0% (2.89) |
| Evolution des prix sur 10 ans: |
0% (2.89) |
| Evolution des prix depuis le début de l'année: |
-16.35% (3.455) |
|
|
Sous-estimation
| Nom |
Signification |
Grade |
| P/S |
0 |
0 |
| P/BV |
-2.42 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
-0.5341 |
0 |
| Total: |
|
2.5 |
|
Efficacité
| Nom |
Signification |
Grade |
| ROA, % |
-155.25 |
0 |
| ROE, % |
1138.6 |
10 |
| Total: |
|
3.33 |
|
|
|
Dividendes
| Nom |
Signification |
Grade |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0 |
|
Devoir
| Nom |
Signification |
Grade |
| Debt/EBITDA |
-0.519 |
10 |
| Total: |
|
9.8 |
|
Impulsion de croissance
| Nom |
Signification |
Grade |
| Rentabilité Revenue, % |
0 |
0 |
| Rentabilité Ebitda, % |
-30.61 |
0 |
| Rentabilité EPS, % |
-4857.39 |
0 |
| Total: |
|
0 |
|
| Superviseur |
Titre d'emploi |
Paiement |
Année de naissance |
| Ms. Dikla Czaczkes Akselbrad |
CEO & Director |
347.88k |
1973 (52 année) |
| Ms. Dalit Hazan |
Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs |
272.38k |
1971 (54 année) |
| Mr. Ori Warshavsky |
Chief Operating Officer - US |
340.89k |
1978 (47 années) |
| Mr. Jonny Missulawin |
Chief Financial Officer |
186.96k |
1987 (38 années) |
| Ms. Maria Rubin |
Vice President of Operations |
N/A |
|
| Mr. Tal Vilnai |
General Counsel & Corporate Secretary |
N/A |
|
| Ms. Rivi Lev-ari |
Vice President of Human Resource |
N/A |
|
| Dr. Jean-Marc Hagai Pharm.D. |
Chief Commercial Officer |
N/A |
|
